Reviewing the Latest in Breast Cancer and Myeloma: Drs Tarantino and Raje
June 2nd 2024OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference
Read More
Dr Tarantino on the Potential Significance of SGN-B7H4V in Breast Cancer
December 4th 2023Paolo Tarantino, MD, discusses ongoing investigations into the use of antibody-drug conjugates targeting B7-H4 vedotin, highlighting their potential significance for the treatment paradigm in breast cancer.
Read More
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Read More
Dr Tarantino on Patient Awareness of the Platinum Shortage in Breast Cancer
August 18th 2023Paolo Tarantino, MD, discusses typical conversations oncologists should have with patients regarding the platinum chemotherapy shortage, as well as the importance of honest communication about treatment regimen changes.
Read More
Dr Tarantino on the Effects of Platinum Chemotherapy Shortages in Breast Cancer
August 9th 2023Paolo Tarantino, MD, discusses how the ongoing shortages of carboplatin and cisplatin in the United States are affecting patients with breast cancer and the importance of overcoming this wave of shortages and preventing this issue from recurring in the future.
Read More
Dr Tarantino on the Expansion of Treatment Options Post-CDK4/6 Inhibition in HR+ Breast Cancer
July 17th 2023Paolo Tarantino, MD, discusses the expansion and selection of effective treatment options for patients with hormone receptor-positive breast cancer who progressed on a CDK 4/6 inhibitor.
Read More
Dr Tarantino on Second-line Treatment Selection in HER2+ Metastatic Breast Cancer
August 16th 2022Paolo Tarantino, MD, researcher, the European Institute of Oncology; clinical research fellow, Dana-Farber Cancer Institute, discusses the options available in the second line for patients with HER2-positive metastatic breast cancer.
Read More